Neulasta Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Podcasts
• Alerts
• Clinical Trials

Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
Condition:   Primary Mediastinal (Thymic) Large B-Cell Lymphoma Interventions:   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide Phosphate;   Biological: Filgrastim;   Biological: Nivolumab;   Biological: Pegfilgrastim;   Drug: Prednisolone;   Drug: Prednisone;   Radiation: Radiation Therapy;   Biological: Rituximab;   Biol ogical: Rituximab and Hyaluronidase Human;   Drug: Vincristine Sulfate Sponsor:   National Cancer Institute (NCI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 18, 2021 Category: Research Source Type: clinical trials